In clinical trials, GI side effects were most common during dose escalation and were generally temporary and mild to moderate in severity (ref), though dedicated data on the duration of sleep-specific disruption is not yet available
*In a 68-week double-blind trial studying once-weekly semaglutide injections (2.4 mg) in 1,961 patients without diabetes and with BMI 30, or BMI 27 with a weight-related condition, the average weight loss was 15%, when paired with diet and exercise changes
Tirzepatide has also shown some promising results with up to 8% absolute reduction in liver fat content in a RCT
Saleh MN, Patel MR, Bauer TM, et al
To learn more about the benefits, risks, & differences of compounded medication substitutes you may visit the FDA Drug Shortage List & FDA Compounding Substitutions Information Page